The Effect of Acutely Administered Propofol on Forced Swim Test Outcomes in Mice.

Objective: Propofol (2,6-diisopropylphenol) is a gamma-aminobutyric acid type A agonist intravenous anesthetic agent used in outpatient settings. Based on anecdotal reports of improved mood in humans following propofol-induced anesthesia, the impact of acute propofol treatment alone or in combinatio...

Descripción completa

Detalles Bibliográficos
Publicado en:Innovations in Clinical Neuroscience Vol. 16; no. 9/10; pp. 22 - 27
Autores principales: DANIEL, DAVID G., DANIEL, NOAH G., DANIEL, DONALD T., FLYNN, LAURA COPELAND, ALLEN, MICHAEL H.
Formato: pictorial research tables/charts Journal Article
Publicado: Matrix Medical Communications, LLC Sep/Oct2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139807197&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 139807197
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        21588333
        DAD5
      jtl: Innovations in Clinical Neuroscience
      issn: 21588333
      maglogo: N
    pubinfo:
      dt: Sep/Oct2019
      vid: 16
      iid: 9/10
      pid: 33670
      pub: Matrix Medical Communications, LLC
      place: West Chester, Pennsylvania
    artinfo:
      ui:
        139807197
        139807197
        139807197
        139807197
      ppf: 22
      ppct: 5
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: The Effect of Acutely Administered Propofol on Forced Swim Test Outcomes in Mice.
      aug:
        au:
          DANIEL, DAVID G.
          DANIEL, NOAH G.
          DANIEL, DONALD T.
          FLYNN, LAURA COPELAND
          ALLEN, MICHAEL H.
        affil: Bioniche Global Development, LLC in McLean, Virginia
      sug:
        subj:
          Drug Therapy, Combination
          Propofol Pharmacodynamics
          Fluoxetine Pharmacodynamics
          Behavior, Animal Drug Effects
          Swimming
          Task Performance and Analysis
          Depression Drug Therapy
          Animal Studies
          Mice
          Administration, Intraperitoneal
          Propofol Administration and Dosage
          Fluoxetine Administration and Dosage
          Normal Saline Administration and Dosage
          Physical Mobility Drug Effects
          Physical Mobility Evaluation
          Videorecording
          Software
          One-Way Analysis of Variance
          Hardiness
          Stress, Psychological Drug Therapy
      ab: Objective: Propofol (2,6-diisopropylphenol) is a gamma-aminobutyric acid type A agonist intravenous anesthetic agent used in outpatient settings. Based on anecdotal reports of improved mood in humans following propofol-induced anesthesia, the impact of acute propofol treatment alone or in combination with subchronic fluoxetine dosing was tested on forced swim test (FST) performance. Design: Seventy-two adult male mice (C57/BL6, CRL-provided) were pretreated daily with saline or fluoxetine (20 mg/kg, intraperitoneally) (21 days for cohort 1; 24 days for cohort 2). At 24 hours after the last pretreatment injection, the mice received saline or propofol (35 or 50 mg/kg, intraperitoneally). Then, 45 minutes later, the mice underwent a five-minute FST. Immobility time was quantified and evaluated with a custom video-analysis software program. Results: A one-way analysis of variance indicated statistically significant effects of propofol on immobility time in cohorts 1 and 2. A comparison performed using Dunnett's method revealed that propofol 50 mg/kg (p < 0.05) but not 35 mg/kg (p = not significant) reduced immobility time as compared with in the saline--saline control group (difference between means of 38.42 and 16.46 seconds, respectively). Conclusion: In comparison with saline, propofol significantly decreased immobility time during the FST, which models depression and resilience to stress. Our preclinical results are consistent with a small open-label study of propofol used in treatment-resistant depression recently reported by Mickey BJ, White AT, Arp AM, et al (2018). Further investigation of propofol regarding its potential antidepressant effects seems warranted.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N